SCHEMBL3339765

SCHEMBL3339765

CCCCCc1cc(NCc2ccccc2)c([N+](=O)[O-])c(N(Cc2ccc(OC)cc2)Cc2ccc(OC)cc2)n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 1/20 0.46
MAPT P10636 6/20 0.44
NPSR1 Q6W5P4 2/20 0.44
SMN1; SMN2 Q16637 3/20 0.43
KDM4E B2RXH2 2/20 0.43
ALDH1A1 P00352 2/20 0.43
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
CRHBP P24387 2/20 0.42
CRHR2 Q13324 2/20 0.42
ACP1 P24666 3/20 0.41
MAPK1 P28482 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
RECQL P46063 1/20 0.40
BLM P54132 1/20 0.40
HTT P42858 3/20 0.39
HSD17B10 Q99714 1/20 0.39
GAA P10253 2/20 0.39
NCF1 P14598 1/20 0.39
NPC1 O15118 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL563121 0.86 KDM4E (0.38) EGFRMAPTSMN1; SMN2KDM4EALDH1A1
SCHEMBL4762917 0.85 ALDH1A1 (0.41) SMN1; SMN2KDM4EALDH1A1MEN1KMT2A
SCHEMBL4762924 0.85 ALDH1A1 (0.41) SMN1; SMN2KDM4EALDH1A1MEN1KMT2A
SCHEMBL3340349 0.84 NCF1 (0.47) MAPTSMN1; SMN2KDM4EALDH1A1MEN1
SCHEMBL563646 0.80 KDM4E (0.39) MAPTSMN1; SMN2KDM4EALDH1A1MEN1
SCHEMBL562979 0.79 PLK1 (0.44) MAPTSMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL3338230 0.73 SMN1; SMN2 (0.40) EGFRMAPTSMN1; SMN2KDM4EALDH1A1
SCHEMBL8123459 0.73 LMNA (0.43) MAPTSMN1; SMN2ALDH1A1MAPK1L3MBTL1
SCHEMBL18398215 0.71 DCTPP1 (0.42) EGFRMAPTNPSR1SMN1; SMN2KDM4E
SCHEMBL563625 0.70 CCNC (0.44) MAPTALDH1A1MEN1KMT2AMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100152230-A1 HYDROXY SUBSTITUTED 1H-IMIDAZOPYRIDINES AND METHODS PFIZER INC. 2010-06-17 US disclosed
EP-1924581-A1 HYDROXY SUBSTITUTED 1H-IMIDAZOPYRIDINES AND METHODS Pfizer, Inc. (US) 2008-05-28 EP disclosed
WO-2007028129-A1 HYDROXY SUBSTITUTED 1H-IMIDAZOPYRIDINES AND METHODS PFIZER INC. (US) 2007-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152230-A1 HYDROXY SUBSTITUTED 1H-IMIDAZOPYRIDINES AND METHODS IL4, IL2, IL4I1 EGFR 3495/4885MAPT 4506/4885NPSR1 3082/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.